Mirati Therapeutics, Inc. (NASDAQ:MRTX) major shareholder Venbio Select Advisor Llc bought 650,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were acquired at an average cost of $13.00 per share, with a total value of $8,450,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded up $4.95 on Friday, reaching $19.00. The company had a trading volume of 3,032,900 shares, compared to its average volume of 551,700. Mirati Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. analysts anticipate that Mirati Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Mirati Therapeutics, Inc. (MRTX) Major Shareholder Venbio Select Advisor Llc Purchases 650,000 Shares” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/mirati-therapeutics-inc-mrtx-major-shareholder-venbio-select-advisor-llc-purchases-650000-shares/1710098.html.

Several research firms have issued reports on MRTX. HC Wainwright reissued a “buy” rating on shares of Mirati Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. ValuEngine raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Jefferies Group LLC set a $5.00 price objective on Mirati Therapeutics and gave the company a “hold” rating in a research note on Friday, August 4th. Finally, Leerink Swann raised Mirati Therapeutics from a “mkt perform” rating to an “outperform” rating and set a $9.00 price objective for the company in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Mirati Therapeutics presently has a consensus rating of “Buy” and an average target price of $13.71.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sabby Management LLC lifted its holdings in Mirati Therapeutics by 2.1% in the second quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after acquiring an additional 5,365 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 11,753 shares during the last quarter. Susquehanna International Group LLP increased its position in shares of Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 16,030 shares during the last quarter. KCG Holdings Inc. bought a new position in shares of Mirati Therapeutics in the first quarter worth approximately $106,000. Finally, Citadel Advisors LLC bought a new position in shares of Mirati Therapeutics in the third quarter worth approximately $268,000. 59.49% of the stock is owned by institutional investors.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.